A Study of GPC3 Redirected Autologous T Cells for Advanced HCC
Status:
Unknown status
Trial end date:
2019-03-01
Target enrollment:
Participant gender:
Summary
Intravenous infusion of CART cells in the treatment of solid tumors may be not a suitable
choice. Because by intravenous infusion, T cells first entered into the blood circulation,
but the number of T cells accumulated at the tumor site is limited, while the probability is
high that CART cells contact with normal tissue where target protein is expressed, leading to
a more potential off-target side effect. In this study, CART cells infused to the body is
mediated by the method of transcatheter arterial infusion(TAI), which is one kind of tumor
intervention therapy pathway. We hope by this means could improve the local CAR-T cell
numbers，meanwhile reduce the potential side effects.